Andere Sprachen Belite Bio, Inc

Aktien

A3DKYL

US07782B1044

BLTE

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:16:19 10.06.2024			% 5 Tage	% 1. Jan.
48,21 ^USD	-0,54 %		-1,01 %	+5,69 %

14.05.	Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
14.05.	Belite Bio, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14.05.
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference	14.05.
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Belite Bio's Q1 Loss Narrows	14.05.
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update	14.05.
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13.05.
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13.05.
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results	08.05.
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant	06.05.
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06.05.
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	06.05.
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	01.05.
Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	26.04.
Belite Bio Announces $25 Million Registered Direct Offering	26.04.
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan	22.04.
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom	18.04.
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease	25.03.
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	22.03.
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22.03.
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Belite Bio, Inc

Aktien

A3DKYL

US07782B1044

BLTE

Andere Sprachen

Filter